{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T04:49:23Z","timestamp":1770785363302,"version":"3.50.0"},"reference-count":40,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>MDD can affect anyone regardless of age, and it often starts during late teens or early adulthood. Although some patients with MDD have an adequate response to medications, only approximately 50% respond to the first treatment, and approximately 30% do not achieve remission despite multiple interventions. Several strategies exist for treating patients who have failed multiple first-line agents, including switching to first-generation antidepressants or to antidepressants unavailable in generic. Other options include augmenting the current antidepressant with other medications such as antipsychotics. Alternatively, augmentation with electroconvulsive therapy, transcranial magnetic stimulation, or esketamine nasal spray can be considered. Prescribing antidepressants unavailable in generic limits accessibility to patients due to cost and prior authorization process. Dextromethorphan\/bupropion, a new combination therapy, has shown promise in the treatment of MDD with efficacy seen as early as week 1. Although commercially available, cost and insurance limitations may necessitate consideration of separate administration of its components. This case report describes a 31-year-old male with a history of treatment-resistant depression and alcohol use disorder who experienced symptom improvement on bupropion and dextromethorphan. This case shares observations and clinical considerations of using such combinations in the management of treatment-resistant depression in the context of substance use disorder.<\/jats:p>","DOI":"10.9740\/mhc.2026.02.030","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:57:51Z","timestamp":1770224271000},"page":"30-33","source":"Crossref","is-referenced-by-count":0,"title":["Clinical benefits and considerations of dextromethorphan and bupropion administered separately for managing depression: A case report"],"prefix":"10.9740","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6584-7091","authenticated-orcid":true,"given":"Parna","family":"Haghparast","sequence":"first","affiliation":[{"name":"(Corresponding author) Associate Professor and Psychiatric Pharmacist, Department of Pharmacy Practice, West Coast University School of Pharmacy Los Angeles, California; Aurora Charter Oak Behavioral Health Center, Covina, California; Cardinal Health, Duplin, Ohio, Phaghparast@westcoastuniversity.edu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0787-1346","authenticated-orcid":true,"given":"Busuyi","family":"Olotu","sequence":"additional","affiliation":[{"name":"Associate Professor, Department of Pharmacy Practice, West Coast University School of Pharmacy Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9558-3036","authenticated-orcid":true,"given":"Carol","family":"Yuan","sequence":"additional","affiliation":[{"name":"Pharmacy Director, Clinical Psychiatric Pharmacist, Department of Pharmacy, Aurora Charter Oak Behavioral Health Center, Covina, California; Cardinal Health, Duplin, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4719","reference":[{"key":"i2168-9709-16-1-30-b01","author":"Major Depression. National Institute of Mental Health (NIMH).","year":"2023","unstructured":"Major Depression. National Institute of Mental Health (NIMH). 2023 Jul. Available from: https:\/\/www.nimh.nih.gov\/health\/statistics\/major-depression#part_2563"},{"issue":"11","key":"i2168-9709-16-1-30-b02","series-title":"Am J Psychiatry","first-page":"1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","unstructured":"Rush AJ,\nTrivedi MH,\nWisniewski SR,\nNierenberg AA,\nStewart JW,\nWarden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-17. DOI: 10.1176\/ajp.2006.163.11.1905"},{"key":"i2168-9709-16-1-30-b03","series-title":"Eur Neuropsychopharmacol","first-page":"696","article-title":"What is the meaning of treatment resistant\/refractory major depression (TRD)? A systematic review of current randomized trials","volume":"17","author":"Berlim","year":"2007","unstructured":"Berlim MT,\nTurecki G. What is the meaning of treatment resistant\/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol. 2007;17:696-707."},{"issue":"9","key":"i2168-9709-16-1-30-b04","series-title":"Can J Psychiatry","first-page":"641","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: R\u00e9seau canadien pour les traitements de l'humeur et de l'anxi\u00e9t\u00e9 (CANMAT) 2023: Mise \u00e0 jour des lignes directrices cliniques pour la prise en charge du trouble d\u00e9pressif majeur chez les adultes","volume":"69","author":"Lam","year":"2024","unstructured":"Lam RW,\nKennedy SH,\nAdams C,\nBahji A,\nBeaulieu S,\nBhat V, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: R\u00e9seau canadien pour les traitements de l'humeur et de l'anxi\u00e9t\u00e9 (CANMAT) 2023: Mise \u00e0 jour des lignes directrices cliniques pour la prise en charge du trouble d\u00e9pressif majeur chez les adultes. Can J Psychiatry. 2024;69(9):641-87. DOI: 10.1177\/07067437241245384"},{"key":"i2168-9709-16-1-30-b05","series-title":"J Affect Disord","first-page":"385","article-title":"Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis","volume":"302","author":"Nu\u00f1ez","year":"2022","unstructured":"Nu\u00f1ez NA,\nJoseph B,\nPahwa M,\nKumar R,\nResendez MG,\nProkop LJ, et al. Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis. J Affect Disord. 2022;302:385-400. DOI: 10.1016\/j.jad.2021.12.134"},{"issue":"11","key":"i2168-9709-16-1-30-b06","series-title":"Psychiatric Services","first-page":"1439","article-title":"What did STAR*D teach us? Results from a Large-Scale, practical, clinical trial for patients with depression","volume":"60","author":"Gaynes","year":"2009","unstructured":"Gaynes BN,\nWarden D,\nTrivedi MH,\nWisniewski SR,\nFava M,\nRush AJ. What did STAR*D teach us? Results from a Large-Scale, practical, clinical trial for patients with depression. Psychiatric Services. 2009;60(11):1439-45. DOI: 10.1176\/ps.2009.60.11.1439"},{"key":"i2168-9709-16-1-30-b07","series-title":"Patient Prefer Adherence","first-page":"369","article-title":"Treatment-resistant depression: therapeutic trends, challenges, and future directions","volume":"6","author":"Al-Harbi","year":"2012","unstructured":"Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369-88."},{"key":"i2168-9709-16-1-30-b08","series-title":"Basic Clin Pharmacol Toxicol","first-page":"227","article-title":"Bupropion as an augmenting agent in patients of depression with partial response","volume":"110","author":"Gulrez","year":"2012","unstructured":"Gulrez G,\nBadyal DK,\nDeswal RS,\nSharma A. Bupropion as an augmenting agent in patients of depression with partial response. Basic Clin Pharmacol Toxicol. 2012;110:227-30. DOI: 10.1111\/j.1742-7843.2011.00788.x"},{"key":"i2168-9709-16-1-30-b09","series-title":"Biol Psychiatry","first-page":"183","article-title":"A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine","volume":"51","author":"Carpenter","year":"2002","unstructured":"Carpenter LL,\nYasmin S,\nPrice LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry. 2002;51:183-8."},{"key":"i2168-9709-16-1-30-b10","article-title":"Axsome therapeutics announces availability of auvelity\u2122, the first and only oral nmda receptor antagonist for the treatment of major depressive disorder in adults","author":"Axsome Therapeutics Inc.","year":"2022","unstructured":"Axsome Therapeutics Inc. Axsome therapeutics announces availability of auvelity\u2122, the first and only oral nmda receptor antagonist for the treatment of major depressive disorder in adults [Internet]. New York: Axsome; 2022 [cited 2025 Sept 16]. Available from: https:\/\/axsometherapeuticsinc.gcs-web.com\/news-releases\/news-release-details\/axsome-therapeutics-announces-fda-approval-auvelitytm-first-and"},{"issue":"4","key":"i2168-9709-16-1-30-b11","series-title":"Clin Psychopharmacol Neurosci","first-page":"609","article-title":"Dextromethorphan-bupropion (Auvelity) for the treatment of major depressive disorder","volume":"21","author":"McCarthy","year":"2023","unstructured":"McCarthy B,\nBunn H,\nSantalucia M,\nWilmouth C,\nMuzyk A,\nSmith CM. Dextromethorphan-bupropion (Auvelity) for the treatment of major depressive disorder. Clin Psychopharmacol Neurosci. 2023;21(4):609-16. DOI: 10.9758\/cpn.23.1081"},{"key":"i2168-9709-16-1-30-b12","article-title":"Package insert [Internet]. Axsome;","author":"Auvelity","year":"2022","unstructured":"Auvelity. Package insert [Internet]. Axsome; 2022 [cited 2025 Sept 24, 2025]. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215430s000lblCorrect3.pdf"},{"issue":"4","key":"i2168-9709-16-1-30-b13","series-title":"J Clin Psychiatry","first-page":"21m14345","article-title":"Efficacy and safety of axs-05 (dextromethorphan-bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (gemini)","volume":"83","author":"Iosifescu","year":"2022","unstructured":"Iosifescu DV,\nJones A,\nO\u2019Gorman C,\nStreicher C,\nFeliz S,\nFava M, et al. Efficacy and safety of axs-05 (dextromethorphan-bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (gemini). J Clin Psychiatry. 2022;83(4):21m14345."},{"issue":"7","key":"i2168-9709-16-1-30-b14","series-title":"Am J Psychiatry","first-page":"490","article-title":"Effect of axs-05 (dextromethorphan-bupropion) in major depressive disorder: a randomized double-blind controlled trial","volume":"179","author":"Tabuteau","year":"2022","unstructured":"Tabuteau H,\nJones A,\nAnderson A,\nJacobson M,\nIosifescu DV. Effect of axs-05 (dextromethorphan-bupropion) in major depressive disorder: a randomized double-blind controlled trial. Am J Psychiatry. 2022;179(7):490-9."},{"key":"i2168-9709-16-1-30-b15","article-title":"In: Lexi-Drugs [database online]","author":"Auvelity","year":"2024","unstructured":"Auvelity. In: Lexi-Drugs [database online]. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc.; 2024 [updated 2025 Dec 3; cited 2025 Dec 3]. Available from: https:\/\/online.lexi.com"},{"issue":"3","key":"i2168-9709-16-1-30-b16","series-title":"Clin Case Rep","first-page":"e7045","article-title":"Improvement of depressive symptoms, after a suicide attempt, with dextromethorphan\/bupropion combination treatment in a patient with treatment-resistant depression and psychiatric comorbidities","volume":"11","author":"Pedraz-Petrozzi","year":"2023","unstructured":"Pedraz-Petrozzi B,\nDeuschle M,\nGilles M. Improvement of depressive symptoms, after a suicide attempt, with dextromethorphan\/bupropion combination treatment in a patient with treatment-resistant depression and psychiatric comorbidities. Clin Case Rep. 2023;11(3):e7045. DOI: 10.1002\/ccr3.7045"},{"key":"i2168-9709-16-1-30-b17","article-title":"Burlington (NC): Labcorp c2025","author":"Dextromethorphan (DM), serum or plasma [Internet].","unstructured":"Dextromethorphan (DM), serum or plasma [Internet]. Burlington (NC): Labcorp c2025 - [cited 2025 May 5]. Available from: https:\/\/www.labcorp.com\/tests\/811893\/dextromethorphan-dm-serum-or-plasma"},{"key":"i2168-9709-16-1-30-b18","article-title":"Alphen aan den Rijn (the Netherlands): Wolters Kluwer c2025","author":"Dextromethorphan [Internet].","unstructured":"Dextromethorphan [Internet]. Alphen aan den Rijn (the Netherlands): Wolters Kluwer c2025 - [cited 2025 Sept 9]. Available from: https:\/\/www.lexicomp.com. Accessed September 9, 2025."},{"key":"i2168-9709-16-1-30-b19","article-title":"Dextromethorphan toxicity [Internet]","author":"Journey","year":"2023","unstructured":"Journey JD,\nAgrawal S,\nStern E. Dextromethorphan toxicity [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2024 Jul 20]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538502\/"},{"key":"i2168-9709-16-1-30-b20","series-title":"Encyclopedia of toxicology","first-page":"45","article-title":"Dextromethorphan","author":"Marraffa","year":"2014","unstructured":"Marraffa JM. Dextromethorphan. In: \nWexler P, ed. Encyclopedia of toxicology. San Diego: Academic Press; 2014. p. 45."},{"key":"i2168-9709-16-1-30-b01","author":"Major Depression. National Institute of Mental Health (NIMH).","year":"2023","unstructured":"Major Depression. National Institute of Mental Health (NIMH). 2023 Jul. Available from: https:\/\/www.nimh.nih.gov\/health\/statistics\/major-depression#part_2563"},{"issue":"11","key":"i2168-9709-16-1-30-b02","series-title":"Am J Psychiatry","first-page":"1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","unstructured":"Rush AJ,\nTrivedi MH,\nWisniewski SR,\nNierenberg AA,\nStewart JW,\nWarden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-17. DOI: 10.1176\/ajp.2006.163.11.1905"},{"key":"i2168-9709-16-1-30-b03","series-title":"Eur Neuropsychopharmacol","first-page":"696","article-title":"What is the meaning of treatment resistant\/refractory major depression (TRD)? A systematic review of current randomized trials","volume":"17","author":"Berlim","year":"2007","unstructured":"Berlim MT,\nTurecki G. What is the meaning of treatment resistant\/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol. 2007;17:696-707."},{"issue":"9","key":"i2168-9709-16-1-30-b04","series-title":"Can J Psychiatry","first-page":"641","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: R\u00e9seau canadien pour les traitements de l'humeur et de l'anxi\u00e9t\u00e9 (CANMAT) 2023: Mise \u00e0 jour des lignes directrices cliniques pour la prise en charge du trouble d\u00e9pressif majeur chez les adultes","volume":"69","author":"Lam","year":"2024","unstructured":"Lam RW,\nKennedy SH,\nAdams C,\nBahji A,\nBeaulieu S,\nBhat V, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: R\u00e9seau canadien pour les traitements de l'humeur et de l'anxi\u00e9t\u00e9 (CANMAT) 2023: Mise \u00e0 jour des lignes directrices cliniques pour la prise en charge du trouble d\u00e9pressif majeur chez les adultes. Can J Psychiatry. 2024;69(9):641-87. DOI: 10.1177\/07067437241245384"},{"key":"i2168-9709-16-1-30-b05","series-title":"J Affect Disord","first-page":"385","article-title":"Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis","volume":"302","author":"Nu\u00f1ez","year":"2022","unstructured":"Nu\u00f1ez NA,\nJoseph B,\nPahwa M,\nKumar R,\nResendez MG,\nProkop LJ, et al. Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis. J Affect Disord. 2022;302:385-400. DOI: 10.1016\/j.jad.2021.12.134"},{"issue":"11","key":"i2168-9709-16-1-30-b06","series-title":"Psychiatric Services","first-page":"1439","article-title":"What did STAR*D teach us? Results from a Large-Scale, practical, clinical trial for patients with depression","volume":"60","author":"Gaynes","year":"2009","unstructured":"Gaynes BN,\nWarden D,\nTrivedi MH,\nWisniewski SR,\nFava M,\nRush AJ. What did STAR*D teach us? Results from a Large-Scale, practical, clinical trial for patients with depression. Psychiatric Services. 2009;60(11):1439-45. DOI: 10.1176\/ps.2009.60.11.1439"},{"key":"i2168-9709-16-1-30-b07","series-title":"Patient Prefer Adherence","first-page":"369","article-title":"Treatment-resistant depression: therapeutic trends, challenges, and future directions","volume":"6","author":"Al-Harbi","year":"2012","unstructured":"Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369-88."},{"key":"i2168-9709-16-1-30-b08","series-title":"Basic Clin Pharmacol Toxicol","first-page":"227","article-title":"Bupropion as an augmenting agent in patients of depression with partial response","volume":"110","author":"Gulrez","year":"2012","unstructured":"Gulrez G,\nBadyal DK,\nDeswal RS,\nSharma A. Bupropion as an augmenting agent in patients of depression with partial response. Basic Clin Pharmacol Toxicol. 2012;110:227-30. DOI: 10.1111\/j.1742-7843.2011.00788.x"},{"key":"i2168-9709-16-1-30-b09","series-title":"Biol Psychiatry","first-page":"183","article-title":"A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine","volume":"51","author":"Carpenter","year":"2002","unstructured":"Carpenter LL,\nYasmin S,\nPrice LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry. 2002;51:183-8."},{"key":"i2168-9709-16-1-30-b10","article-title":"Axsome therapeutics announces availability of auvelity\u2122, the first and only oral nmda receptor antagonist for the treatment of major depressive disorder in adults","author":"Axsome Therapeutics Inc.","year":"2022","unstructured":"Axsome Therapeutics Inc. Axsome therapeutics announces availability of auvelity\u2122, the first and only oral nmda receptor antagonist for the treatment of major depressive disorder in adults [Internet]. New York: Axsome; 2022 [cited 2025 Sept 16]. Available from: https:\/\/axsometherapeuticsinc.gcs-web.com\/news-releases\/news-release-details\/axsome-therapeutics-announces-fda-approval-auvelitytm-first-and"},{"issue":"4","key":"i2168-9709-16-1-30-b11","series-title":"Clin Psychopharmacol Neurosci","first-page":"609","article-title":"Dextromethorphan-bupropion (Auvelity) for the treatment of major depressive disorder","volume":"21","author":"McCarthy","year":"2023","unstructured":"McCarthy B,\nBunn H,\nSantalucia M,\nWilmouth C,\nMuzyk A,\nSmith CM. Dextromethorphan-bupropion (Auvelity) for the treatment of major depressive disorder. Clin Psychopharmacol Neurosci. 2023;21(4):609-16. DOI: 10.9758\/cpn.23.1081"},{"key":"i2168-9709-16-1-30-b12","article-title":"Package insert [Internet]. Axsome;","author":"Auvelity","year":"2022","unstructured":"Auvelity. Package insert [Internet]. Axsome; 2022 [cited 2025 Sept 24, 2025]. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215430s000lblCorrect3.pdf"},{"issue":"4","key":"i2168-9709-16-1-30-b13","series-title":"J Clin Psychiatry","first-page":"21m14345","article-title":"Efficacy and safety of axs-05 (dextromethorphan-bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (gemini)","volume":"83","author":"Iosifescu","year":"2022","unstructured":"Iosifescu DV,\nJones A,\nO\u2019Gorman C,\nStreicher C,\nFeliz S,\nFava M, et al. Efficacy and safety of axs-05 (dextromethorphan-bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (gemini). J Clin Psychiatry. 2022;83(4):21m14345."},{"issue":"7","key":"i2168-9709-16-1-30-b14","series-title":"Am J Psychiatry","first-page":"490","article-title":"Effect of axs-05 (dextromethorphan-bupropion) in major depressive disorder: a randomized double-blind controlled trial","volume":"179","author":"Tabuteau","year":"2022","unstructured":"Tabuteau H,\nJones A,\nAnderson A,\nJacobson M,\nIosifescu DV. Effect of axs-05 (dextromethorphan-bupropion) in major depressive disorder: a randomized double-blind controlled trial. Am J Psychiatry. 2022;179(7):490-9."},{"key":"i2168-9709-16-1-30-b15","article-title":"In: Lexi-Drugs [database online]","author":"Auvelity","year":"2024","unstructured":"Auvelity. In: Lexi-Drugs [database online]. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc.; 2024 [updated 2025 Dec 3; cited 2025 Dec 3]. Available from: https:\/\/online.lexi.com"},{"issue":"3","key":"i2168-9709-16-1-30-b16","series-title":"Clin Case Rep","first-page":"e7045","article-title":"Improvement of depressive symptoms, after a suicide attempt, with dextromethorphan\/bupropion combination treatment in a patient with treatment-resistant depression and psychiatric comorbidities","volume":"11","author":"Pedraz-Petrozzi","year":"2023","unstructured":"Pedraz-Petrozzi B,\nDeuschle M,\nGilles M. Improvement of depressive symptoms, after a suicide attempt, with dextromethorphan\/bupropion combination treatment in a patient with treatment-resistant depression and psychiatric comorbidities. Clin Case Rep. 2023;11(3):e7045. DOI: 10.1002\/ccr3.7045"},{"key":"i2168-9709-16-1-30-b17","article-title":"Burlington (NC): Labcorp c2025","author":"Dextromethorphan (DM), serum or plasma [Internet].","unstructured":"Dextromethorphan (DM), serum or plasma [Internet]. Burlington (NC): Labcorp c2025 - [cited 2025 May 5]. Available from: https:\/\/www.labcorp.com\/tests\/811893\/dextromethorphan-dm-serum-or-plasma"},{"key":"i2168-9709-16-1-30-b18","article-title":"Alphen aan den Rijn (the Netherlands): Wolters Kluwer c2025","author":"Dextromethorphan [Internet].","unstructured":"Dextromethorphan [Internet]. Alphen aan den Rijn (the Netherlands): Wolters Kluwer c2025 - [cited 2025 Sept 9]. Available from: https:\/\/www.lexicomp.com. Accessed September 9, 2025."},{"key":"i2168-9709-16-1-30-b19","article-title":"Dextromethorphan toxicity [Internet]","author":"Journey","year":"2023","unstructured":"Journey JD,\nAgrawal S,\nStern E. Dextromethorphan toxicity [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2024 Jul 20]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538502\/"},{"key":"i2168-9709-16-1-30-b20","series-title":"Encyclopedia of toxicology","first-page":"45","article-title":"Dextromethorphan","author":"Marraffa","year":"2014","unstructured":"Marraffa JM. Dextromethorphan. In: \nWexler P, ed. Encyclopedia of toxicology. San Diego: Academic Press; 2014. p. 45."}],"container-title":["Mental Health Clinician"],"original-title":[],"link":[{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/16\/1\/article-p30.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/mhc.kglmeridian.com\/downloadpdf\/journals\/mhcl\/16\/1\/article-p30.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/mhc.kglmeridian.com\/downloadpdf\/journals\/mhcl\/16\/1\/article-p30.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:51:33Z","timestamp":1770771093000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/16\/1\/article-p30.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":40,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.9740\/mhc.2026.02.030","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}